| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Opioid-Related Disorders | 25 | 2024 | 168 | 7.130 |
Why?
|
| Substance-Related Disorders | 29 | 2022 | 439 | 5.960 |
Why?
|
| Analgesics, Opioid | 34 | 2024 | 241 | 5.720 |
Why?
|
| Patient Protection and Affordable Care Act | 7 | 2020 | 51 | 3.160 |
Why?
|
| Buprenorphine | 7 | 2023 | 48 | 2.690 |
Why?
|
| Delivery of Health Care, Integrated | 11 | 2024 | 567 | 2.660 |
Why?
|
| HIV Infections | 19 | 2024 | 695 | 2.570 |
Why?
|
| Humans | 110 | 2024 | 18430 | 2.320 |
Why?
|
| Adult | 66 | 2024 | 7910 | 2.180 |
Why?
|
| Female | 84 | 2024 | 13136 | 2.070 |
Why?
|
| Male | 73 | 2024 | 10440 | 2.010 |
Why?
|
| Mental Disorders | 7 | 2024 | 295 | 1.980 |
Why?
|
| Substance Abuse Treatment Centers | 12 | 2012 | 75 | 1.920 |
Why?
|
| California | 30 | 2024 | 2365 | 1.820 |
Why?
|
| Middle Aged | 54 | 2024 | 8284 | 1.730 |
Why?
|
| Chronic Pain | 10 | 2024 | 128 | 1.730 |
Why?
|
| Alcoholism | 10 | 2024 | 350 | 1.630 |
Why?
|
| Patient Acceptance of Health Care | 8 | 2024 | 407 | 1.500 |
Why?
|
| Electronic Health Records | 14 | 2024 | 747 | 1.460 |
Why?
|
| Marijuana Abuse | 5 | 2024 | 41 | 1.440 |
Why?
|
| Primary Health Care | 16 | 2024 | 848 | 1.400 |
Why?
|
| Emergency Service, Hospital | 5 | 2024 | 382 | 1.270 |
Why?
|
| Opiate Substitution Treatment | 7 | 2024 | 45 | 1.250 |
Why?
|
| Ambulatory Care | 7 | 2012 | 266 | 1.220 |
Why?
|
| Young Adult | 26 | 2024 | 2518 | 1.190 |
Why?
|
| Adolescent | 31 | 2024 | 3798 | 1.180 |
Why?
|
| Telemedicine | 4 | 2023 | 184 | 1.170 |
Why?
|
| Marijuana Use | 6 | 2024 | 33 | 1.120 |
Why?
|
| Pain | 10 | 2024 | 84 | 1.100 |
Why?
|
| Drug Overdose | 5 | 2020 | 57 | 1.070 |
Why?
|
| Aged | 30 | 2024 | 6417 | 1.060 |
Why?
|
| Health Services Accessibility | 7 | 2020 | 320 | 1.030 |
Why?
|
| Health Care Costs | 3 | 2017 | 251 | 1.030 |
Why?
|
| Registries | 3 | 2018 | 490 | 1.030 |
Why?
|
| Adolescent Behavior | 4 | 2024 | 129 | 1.020 |
Why?
|
| Retrospective Studies | 21 | 2024 | 2550 | 0.970 |
Why?
|
| Delivery of Health Care | 5 | 2024 | 444 | 0.970 |
Why?
|
| Prenatal Care | 2 | 2024 | 134 | 0.930 |
Why?
|
| Radiculopathy | 1 | 2023 | 5 | 0.920 |
Why?
|
| Musculoskeletal Pain | 1 | 2023 | 28 | 0.900 |
Why?
|
| United States | 22 | 2022 | 4164 | 0.880 |
Why?
|
| Insurance Coverage | 3 | 2020 | 136 | 0.880 |
Why?
|
| Health Services | 3 | 2016 | 117 | 0.820 |
Why?
|
| Cohort Studies | 15 | 2024 | 2672 | 0.770 |
Why?
|
| Alcohol Drinking | 4 | 2024 | 375 | 0.760 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2021 | 13 | 0.750 |
Why?
|
| Social Class | 2 | 2023 | 125 | 0.750 |
Why?
|
| Health Policy | 2 | 2018 | 136 | 0.710 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2020 | 24 | 0.700 |
Why?
|
| Treatment Outcome | 15 | 2021 | 1296 | 0.690 |
Why?
|
| Depressive Disorder, Major | 2 | 2020 | 127 | 0.690 |
Why?
|
| Marijuana Smoking | 2 | 2018 | 50 | 0.680 |
Why?
|
| Cross-Sectional Studies | 11 | 2024 | 1360 | 0.670 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2024 | 350 | 0.630 |
Why?
|
| Alcohol-Related Disorders | 2 | 2017 | 56 | 0.630 |
Why?
|
| Family | 2 | 2017 | 120 | 0.630 |
Why?
|
| Prescription Drug Misuse | 1 | 2018 | 11 | 0.610 |
Why?
|
| Self-Help Groups | 3 | 2013 | 32 | 0.600 |
Why?
|
| Patient Admission | 1 | 2017 | 76 | 0.580 |
Why?
|
| Drug Users | 1 | 2017 | 7 | 0.580 |
Why?
|
| Women's Health Services | 2 | 2008 | 21 | 0.580 |
Why?
|
| Depression | 7 | 2017 | 518 | 0.570 |
Why?
|
| Outpatients | 4 | 2023 | 111 | 0.570 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2009 | 95 | 0.560 |
Why?
|
| Self Report | 7 | 2024 | 256 | 0.560 |
Why?
|
| Smoking | 2 | 2017 | 494 | 0.560 |
Why?
|
| Inpatients | 1 | 2017 | 80 | 0.550 |
Why?
|
| Income | 1 | 2017 | 98 | 0.550 |
Why?
|
| Medical Marijuana | 3 | 2022 | 24 | 0.550 |
Why?
|
| Cannabis | 5 | 2024 | 78 | 0.550 |
Why?
|
| Disease Management | 1 | 2016 | 143 | 0.530 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 2003 | 0.520 |
Why?
|
| Analgesics | 3 | 2022 | 28 | 0.520 |
Why?
|
| Deductibles and Coinsurance | 1 | 2016 | 31 | 0.520 |
Why?
|
| Mental Health Services | 3 | 2024 | 161 | 0.510 |
Why?
|
| Prevalence | 9 | 2024 | 911 | 0.500 |
Why?
|
| Pain Management | 5 | 2024 | 59 | 0.500 |
Why?
|
| Insurance, Health | 2 | 2016 | 217 | 0.490 |
Why?
|
| Patient Compliance | 6 | 2013 | 318 | 0.480 |
Why?
|
| Longitudinal Studies | 6 | 2020 | 724 | 0.480 |
Why?
|
| Legislation, Drug | 2 | 2024 | 10 | 0.480 |
Why?
|
| Respiration, Artificial | 2 | 2024 | 38 | 0.470 |
Why?
|
| Tobacco Use Cessation | 2 | 2017 | 23 | 0.460 |
Why?
|
| Patient Participation | 3 | 2024 | 144 | 0.460 |
Why?
|
| Drug Prescriptions | 5 | 2017 | 157 | 0.450 |
Why?
|
| Social Support | 2 | 2012 | 214 | 0.430 |
Why?
|
| Hospitalization | 2 | 2024 | 847 | 0.430 |
Why?
|
| Hallucinogens | 2 | 2024 | 23 | 0.420 |
Why?
|
| Sex Factors | 9 | 2017 | 661 | 0.410 |
Why?
|
| Pandemics | 6 | 2024 | 292 | 0.410 |
Why?
|
| Friends | 1 | 2012 | 10 | 0.410 |
Why?
|
| Interpersonal Relations | 1 | 2012 | 42 | 0.400 |
Why?
|
| Health Care Surveys | 5 | 2022 | 247 | 0.400 |
Why?
|
| Private Sector | 3 | 2007 | 16 | 0.400 |
Why?
|
| Peer Group | 1 | 2012 | 48 | 0.400 |
Why?
|
| National Institute on Drug Abuse (U.S.) | 3 | 2021 | 5 | 0.390 |
Why?
|
| Methadone | 2 | 2008 | 11 | 0.380 |
Why?
|
| Accreditation | 2 | 2008 | 5 | 0.370 |
Why?
|
| State Health Plans | 1 | 2010 | 44 | 0.360 |
Why?
|
| Risk Factors | 11 | 2018 | 3449 | 0.350 |
Why?
|
| Neoplasms | 4 | 2011 | 457 | 0.350 |
Why?
|
| Anti-Retroviral Agents | 3 | 2009 | 80 | 0.340 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2009 | 65 | 0.340 |
Why?
|
| Medicaid | 3 | 2022 | 211 | 0.320 |
Why?
|
| Surveys and Questionnaires | 8 | 2024 | 1389 | 0.320 |
Why?
|
| Research Design | 2 | 2021 | 402 | 0.310 |
Why?
|
| Depressive Disorder | 4 | 2018 | 231 | 0.300 |
Why?
|
| Respiratory Insufficiency | 2 | 2024 | 16 | 0.300 |
Why?
|
| Narcotics | 1 | 2007 | 7 | 0.300 |
Why?
|
| Self Care | 1 | 2008 | 175 | 0.290 |
Why?
|
| Licensure | 1 | 2007 | 5 | 0.290 |
Why?
|
| Comorbidity | 4 | 2017 | 619 | 0.290 |
Why?
|
| Psychotherapy | 1 | 2007 | 59 | 0.280 |
Why?
|
| Papillomavirus Infections | 2 | 2020 | 136 | 0.270 |
Why?
|
| Women's Health | 1 | 2007 | 207 | 0.270 |
Why?
|
| Managed Care Programs | 3 | 2010 | 347 | 0.270 |
Why?
|
| Pregnancy | 4 | 2024 | 1516 | 0.270 |
Why?
|
| Age Factors | 8 | 2024 | 965 | 0.270 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 188 | 0.260 |
Why?
|
| Prescription Drugs | 2 | 2020 | 33 | 0.250 |
Why?
|
| Consensus | 2 | 2024 | 41 | 0.250 |
Why?
|
| Cannabinoids | 1 | 2024 | 6 | 0.240 |
Why?
|
| Child | 5 | 2022 | 2571 | 0.240 |
Why?
|
| Vomiting | 1 | 2024 | 12 | 0.240 |
Why?
|
| Patient-Centered Care | 1 | 2007 | 228 | 0.240 |
Why?
|
| Fentanyl | 1 | 2024 | 1 | 0.240 |
Why?
|
| Commerce | 1 | 2024 | 49 | 0.240 |
Why?
|
| Regression Analysis | 3 | 2017 | 319 | 0.240 |
Why?
|
| Headache | 1 | 2023 | 14 | 0.230 |
Why?
|
| Back Pain | 1 | 2023 | 33 | 0.230 |
Why?
|
| Prescriptions | 1 | 2023 | 28 | 0.230 |
Why?
|
| Logistic Models | 6 | 2017 | 962 | 0.230 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2013 | 55 | 0.230 |
Why?
|
| Ecological Momentary Assessment | 1 | 2023 | 3 | 0.220 |
Why?
|
| Anus Neoplasms | 2 | 2012 | 26 | 0.220 |
Why?
|
| Efficiency, Organizational | 1 | 2003 | 36 | 0.220 |
Why?
|
| Insurance | 1 | 2022 | 5 | 0.220 |
Why?
|
| Pain, Postoperative | 2 | 2019 | 16 | 0.220 |
Why?
|
| Ethnic Groups | 3 | 2009 | 501 | 0.220 |
Why?
|
| Qualitative Research | 1 | 2024 | 272 | 0.210 |
Why?
|
| Behavior, Addictive | 1 | 2022 | 12 | 0.210 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2013 | 24 | 0.210 |
Why?
|
| Ownership | 3 | 2008 | 15 | 0.210 |
Why?
|
| Patient Discharge | 1 | 2024 | 153 | 0.210 |
Why?
|
| Cultural Diversity | 1 | 2002 | 17 | 0.200 |
Why?
|
| Crisis Intervention | 1 | 2022 | 16 | 0.200 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 598 | 0.200 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 64 | 0.200 |
Why?
|
| HIV Seropositivity | 3 | 2006 | 31 | 0.200 |
Why?
|
| Ambulatory Care Facilities | 1 | 2002 | 77 | 0.200 |
Why?
|
| Quality of Life | 2 | 2024 | 529 | 0.190 |
Why?
|
| Nurse Administrators | 1 | 2021 | 8 | 0.190 |
Why?
|
| Delphi Technique | 1 | 2021 | 33 | 0.190 |
Why?
|
| Natural Language Processing | 1 | 2022 | 57 | 0.190 |
Why?
|
| Drug Administration Schedule | 5 | 2015 | 100 | 0.190 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 91 | 0.190 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2021 | 56 | 0.180 |
Why?
|
| Alphapapillomavirus | 1 | 2020 | 14 | 0.180 |
Why?
|
| Community Health Services | 1 | 2021 | 86 | 0.180 |
Why?
|
| Activities of Daily Living | 2 | 2018 | 96 | 0.180 |
Why?
|
| Hepatitis C | 1 | 2021 | 65 | 0.180 |
Why?
|
| Case-Control Studies | 3 | 2020 | 1173 | 0.180 |
Why?
|
| Anxiety Disorders | 1 | 2020 | 93 | 0.180 |
Why?
|
| Time Factors | 7 | 2013 | 1136 | 0.180 |
Why?
|
| Anti-Anxiety Agents | 1 | 2019 | 4 | 0.180 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2019 | 7 | 0.170 |
Why?
|
| Orthopedic Procedures | 1 | 2019 | 6 | 0.170 |
Why?
|
| Social Environment | 2 | 2012 | 90 | 0.170 |
Why?
|
| Demography | 2 | 2012 | 108 | 0.170 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2013 | 178 | 0.170 |
Why?
|
| Mortality | 2 | 2017 | 123 | 0.170 |
Why?
|
| Postoperative Care | 1 | 2019 | 20 | 0.170 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 50 | 0.170 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 57 | 0.170 |
Why?
|
| Length of Stay | 2 | 2012 | 183 | 0.170 |
Why?
|
| Motivation | 2 | 2012 | 137 | 0.170 |
Why?
|
| Benzodiazepines | 1 | 2019 | 26 | 0.170 |
Why?
|
| Anti-HIV Agents | 2 | 2011 | 154 | 0.170 |
Why?
|
| Cesarean Section | 1 | 2019 | 30 | 0.170 |
Why?
|
| Long-Term Care | 4 | 2015 | 22 | 0.170 |
Why?
|
| Gemfibrozil | 1 | 2009 | 5 | 0.170 |
Why?
|
| HIV Seronegativity | 2 | 2006 | 9 | 0.170 |
Why?
|
| Mental Health | 2 | 2012 | 168 | 0.170 |
Why?
|
| Hypolipidemic Agents | 1 | 2009 | 44 | 0.160 |
Why?
|
| Sex Distribution | 2 | 2016 | 198 | 0.160 |
Why?
|
| Follow-Up Studies | 4 | 2012 | 1269 | 0.160 |
Why?
|
| Odds Ratio | 5 | 2022 | 701 | 0.160 |
Why?
|
| Drug Utilization | 4 | 2015 | 134 | 0.160 |
Why?
|
| Age Distribution | 2 | 2016 | 261 | 0.160 |
Why?
|
| Papillomavirus Vaccines | 1 | 2020 | 118 | 0.160 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2020 | 127 | 0.160 |
Why?
|
| Child Care | 2 | 2008 | 12 | 0.160 |
Why?
|
| Dyslipidemias | 1 | 2009 | 65 | 0.160 |
Why?
|
| Health Services Research | 3 | 2020 | 264 | 0.150 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 673 | 0.150 |
Why?
|
| Prospective Studies | 4 | 2024 | 1314 | 0.150 |
Why?
|
| Motivational Interviewing | 1 | 2017 | 32 | 0.150 |
Why?
|
| Quality Improvement | 1 | 2019 | 207 | 0.150 |
Why?
|
| Continental Population Groups | 1 | 2009 | 315 | 0.150 |
Why?
|
| Suicidal Ideation | 1 | 2018 | 100 | 0.140 |
Why?
|
| Clinical Coding | 1 | 2017 | 11 | 0.140 |
Why?
|
| Forecasting | 1 | 2017 | 80 | 0.140 |
Why?
|
| Smoking Prevention | 1 | 2017 | 55 | 0.140 |
Why?
|
| Tobacco Use Disorder | 1 | 2017 | 49 | 0.140 |
Why?
|
| Drug Compounding | 1 | 2016 | 4 | 0.140 |
Why?
|
| Oxycodone | 1 | 2016 | 2 | 0.140 |
Why?
|
| International Classification of Diseases | 1 | 2017 | 87 | 0.140 |
Why?
|
| Human papillomavirus 16 | 1 | 2006 | 7 | 0.140 |
Why?
|
| Washington | 3 | 2017 | 388 | 0.140 |
Why?
|
| HIV-1 | 1 | 2006 | 71 | 0.130 |
Why?
|
| HIV | 1 | 2006 | 26 | 0.130 |
Why?
|
| RNA, Viral | 1 | 2016 | 64 | 0.130 |
Why?
|
| Incidence | 3 | 2013 | 1314 | 0.130 |
Why?
|
| Cost Sharing | 1 | 2016 | 40 | 0.130 |
Why?
|
| Chronic Disease | 4 | 2012 | 468 | 0.130 |
Why?
|
| Antibodies, Viral | 1 | 2006 | 65 | 0.130 |
Why?
|
| Organizational Affiliation | 2 | 2007 | 2 | 0.130 |
Why?
|
| Algorithms | 1 | 2017 | 241 | 0.130 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2016 | 110 | 0.130 |
Why?
|
| Anxiety | 1 | 2016 | 156 | 0.130 |
Why?
|
| Psychometrics | 3 | 2012 | 124 | 0.130 |
Why?
|
| Mass Screening | 2 | 2022 | 690 | 0.120 |
Why?
|
| Health Personnel | 1 | 2015 | 126 | 0.120 |
Why?
|
| Patients | 1 | 2014 | 38 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2017 | 1478 | 0.110 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2012 | 129 | 0.100 |
Why?
|
| Telephone | 3 | 2022 | 179 | 0.100 |
Why?
|
| Hypnotics and Sedatives | 1 | 2012 | 17 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 83 | 0.100 |
Why?
|
| Documentation | 2 | 2022 | 45 | 0.100 |
Why?
|
| Disabled Persons | 1 | 2012 | 41 | 0.100 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2012 | 70 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2022 | 237 | 0.090 |
Why?
|
| Stress, Psychological | 1 | 2012 | 147 | 0.090 |
Why?
|
| Health Status | 1 | 2012 | 328 | 0.090 |
Why?
|
| Religion | 1 | 2009 | 14 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2012 | 267 | 0.080 |
Why?
|
| Asthma | 1 | 2012 | 390 | 0.080 |
Why?
|
| Confidence Intervals | 3 | 2014 | 253 | 0.080 |
Why?
|
| Continuity of Patient Care | 1 | 2009 | 112 | 0.080 |
Why?
|
| Health Surveys | 3 | 2015 | 269 | 0.080 |
Why?
|
| Health Planning | 1 | 2007 | 17 | 0.070 |
Why?
|
| Case Management | 1 | 2007 | 37 | 0.070 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2007 | 1 | 0.070 |
Why?
|
| United States Food and Drug Administration | 1 | 2007 | 36 | 0.070 |
Why?
|
| Needs Assessment | 1 | 2007 | 69 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2012 | 131 | 0.070 |
Why?
|
| Biomarkers | 2 | 2009 | 308 | 0.070 |
Why?
|
| Reproductive Medicine | 1 | 2006 | 1 | 0.070 |
Why?
|
| Social Work | 1 | 2006 | 13 | 0.070 |
Why?
|
| Behavior Therapy | 1 | 2007 | 155 | 0.070 |
Why?
|
| Public Policy | 1 | 2024 | 17 | 0.060 |
Why?
|
| Administration, Intravenous | 1 | 2024 | 7 | 0.060 |
Why?
|
| Social Norms | 1 | 2024 | 3 | 0.060 |
Why?
|
| Virus Replication | 2 | 2011 | 12 | 0.060 |
Why?
|
| Public Sector | 1 | 2003 | 9 | 0.060 |
Why?
|
| Urban Health | 1 | 2003 | 40 | 0.060 |
Why?
|
| Epidemiologic Methods | 2 | 2009 | 87 | 0.060 |
Why?
|
| Intensive Care Units | 1 | 2024 | 106 | 0.060 |
Why?
|
| Models, Organizational | 1 | 2003 | 65 | 0.050 |
Why?
|
| Cannabinoid Receptor Agonists | 1 | 2022 | 8 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 83 | 0.050 |
Why?
|
| Biopsy | 1 | 2013 | 75 | 0.050 |
Why?
|
| Viral Load | 2 | 2011 | 135 | 0.050 |
Why?
|
| Melanoma | 1 | 2013 | 37 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 226 | 0.050 |
Why?
|
| Confidentiality | 1 | 2022 | 30 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 65 | 0.050 |
Why?
|
| North America | 1 | 2012 | 42 | 0.050 |
Why?
|
| Statistics as Topic | 2 | 2012 | 66 | 0.050 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 54 | 0.050 |
Why?
|
| Patient Selection | 1 | 2013 | 198 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2002 | 108 | 0.050 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 2 | 2013 | 28 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 392 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 160 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2002 | 327 | 0.050 |
Why?
|
| Endpoint Determination | 1 | 2021 | 10 | 0.050 |
Why?
|
| Infection Control | 1 | 2020 | 10 | 0.050 |
Why?
|
| Communication | 1 | 2022 | 202 | 0.050 |
Why?
|
| Sexual Behavior | 1 | 2012 | 123 | 0.050 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 47 | 0.050 |
Why?
|
| Temperance | 2 | 2012 | 24 | 0.050 |
Why?
|
| Counseling | 1 | 2022 | 197 | 0.040 |
Why?
|
| Naltrexone | 1 | 2020 | 17 | 0.040 |
Why?
|
| Lorazepam | 1 | 2019 | 4 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 41 | 0.040 |
Why?
|
| Immunologic Surveillance | 1 | 2009 | 2 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2009 | 6 | 0.040 |
Why?
|
| Triglycerides | 1 | 2009 | 87 | 0.040 |
Why?
|
| Medicare | 1 | 2020 | 214 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2009 | 125 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2019 | 244 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 133 | 0.040 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2017 | 31 | 0.040 |
Why?
|
| Risk | 1 | 2009 | 552 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2012 | 1143 | 0.040 |
Why?
|
| Death Certificates | 1 | 2017 | 19 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2009 | 211 | 0.040 |
Why?
|
| Military Personnel | 1 | 2006 | 12 | 0.030 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2006 | 17 | 0.030 |
Why?
|
| Oregon | 1 | 2017 | 222 | 0.030 |
Why?
|
| HIV Antibodies | 1 | 2006 | 4 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2017 | 109 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 321 | 0.030 |
Why?
|
| Inservice Training | 1 | 2015 | 15 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 365 | 0.030 |
Why?
|
| Leadership | 1 | 2015 | 45 | 0.030 |
Why?
|
| Disease Progression | 1 | 2006 | 271 | 0.030 |
Why?
|
| Vaccination | 1 | 2020 | 674 | 0.030 |
Why?
|
| Physicians | 1 | 2015 | 141 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2015 | 180 | 0.030 |
Why?
|
| Attitude | 1 | 2014 | 33 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2014 | 167 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2006 | 554 | 0.030 |
Why?
|
| Educational Status | 1 | 2014 | 205 | 0.030 |
Why?
|
| African Americans | 1 | 2006 | 490 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 232 | 0.030 |
Why?
|
| Hospitals, Voluntary | 1 | 2012 | 4 | 0.030 |
Why?
|
| Cell Count | 1 | 2012 | 10 | 0.030 |
Why?
|
| San Francisco | 1 | 2012 | 68 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2012 | 71 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2012 | 82 | 0.020 |
Why?
|
| Self Administration | 1 | 2011 | 12 | 0.020 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2011 | 27 | 0.020 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2009 | 18 | 0.020 |
Why?
|
| Morphine | 1 | 2009 | 8 | 0.020 |
Why?
|
| Time | 1 | 2009 | 20 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2009 | 52 | 0.020 |
Why?
|
| Data Collection | 1 | 2009 | 275 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 743 | 0.020 |
Why?
|